AUROBAC Successfully Completes Phase 1 Clinical Trial of ATX101 and Prepares for Phase 2
ATX101 is a potential first-in-class treatment, addressing shock, organ failure and mortality in sepsis.
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
